Cargando…
Review of Lutetium-177-labeled Anti-prostate-specific Membrane Antigen Monoclonal Antibody J591 for the Treatment of Metastatic Castration-resistant Prostate Cancer
Prostate cancer is the most common non-cutaneous cancer in men in the United States and is the second most common cause of cancer deaths after lung cancer in men. Despite all advances in the field of prostate cancer imaging and treatment, currently, it is sub-optimally responsive to all available tr...
Autores principales: | Niaz, Muhammad O, Sun, Michael, Ramirez-Fort, Marigdalia K, Niaz, Muhammad J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7100619/ https://www.ncbi.nlm.nih.gov/pubmed/32257655 http://dx.doi.org/10.7759/cureus.7107 |
Ejemplares similares
-
Prostate-specific Membrane Antigen Based Antibody-drug Conjugates for Metastatic Castration-resistance Prostate Cancer
por: Niaz, Muhammad O, et al.
Publicado: (2020) -
Review of 177Lu-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer
por: Sun, Michael, et al.
Publicado: (2020) -
Lutetium-177 prostate-specific membrane antigen-617 theranostics: New therapeutic hope in metastatic castrate-resistant prostate cancer?
por: Ranjan, Satish Kumar
Publicado: (2020) -
Lutetium-177 Prostate-Specific Membrane Antigen-617 Treatment in Metastatic Castration-Resistant Prostate Adenocarcinoma: Results of Single-Center Experience
por: Maman, Adem
Publicado: (2023) -
Neuroendocrine Tumor Therapy with Lutetium-177: A Literature Review
por: Maqsood, Muhammad Haisum, et al.
Publicado: (2019)